



Current Status of Lung Cancer Research

**M. D. Jawad Noor^{a*}, Owen R. Thornton^b
and Kimberly Morton Cuthrell^c**

^a St. Dominic Hospital, Jackson, Mississippi, United States.

^b University of North Carolina at Chapel Hill, United States.

^c Saint James School Of Medicine, United States.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/96387>

Review Article

Received: 10/12/2022

Accepted: 15/02/2023

Published: 21/02/2023

ABSTRACT

One of the most common cancers to cause death worldwide is lung cancer. Lung carcinoma, another name for lung cancer, is a malignant lung tumor that is characterized by unchecked cell proliferation in lung tissues. This tumor has the potential to metastasize, or expand outside of the lung, into neighboring tissue or other sections of the body, if left untreated. The majority of primary lung malignancies, also known as cancers that begin in the lung, are carcinomas that develop from epithelial cells. Small-cell lung cancer (SCLC) and non-small-cell lung carcinoma (NSCLC) are the two main primary kinds. Lung cancer is primarily caused by prolonged cigarette smoke exposure (85% of cases). Approximately 10-15% of occurrences include non-smokers. These situations are frequently brought on by a confluence of genetic predispositions and exposure to asbestos, radon gas, or other environmental pollutants such as secondhand smoke. This article provides an overview of lung cancer's epidemiology, causes, forms, symptoms, and treatments.

Keywords: Lung cancer; small-cell lung cancer; non-small-cell lung carcinoma; adenocarcinoma; squamous cell carcinoma; large cell carcinoma.

1. INTRODUCTION

Cancer is a condition in which the body's cells proliferate unchecked. Lung cancer is the name

for cancer that first appears in the lungs. In addition to lymph nodes and other body organs including the brain, lung cancer can also start in the lungs. Lung cancer can potentially spread

*Corresponding author: E-mail: Jawadnoor@gmail.com;

from other organs. Metastases are cancer cells that have spread from one organ to another [1-4]. Since 98–99% of all lung cancers are carcinomas, lung cancer is also known as lung carcinoma, and it is a malignant lung tumor characterized by unchecked cell proliferation in lung tissues. Lung carcinomas develop from epithelial tissues or from epithelial cells that have undergone malignant transformation. Other lung cancers, like the uncommon sarcomas of the lung, are caused by the malignant transformation of connective tissues, which develop from mesenchymal cells and include fat, muscle, and bone. Rarely, lung cancer can also develop from lymphomas and melanomas (derived from lymphoid and melanocyte cell lineages) [5].

One of the biggest causes of cancer-related deaths worldwide is lung cancer. Lung cancer has the highest prevalence among all cancers, and its cases are continuously increasing [6]. Tumors coming from the bronchi or the lung parenchyma are referred to as bronchogenic carcinomas or lung cancer. Bronchogenic ranks among the top reasons for cancer-related fatalities in the United States of America (USA). Lung cancer has been the cause of more female fatalities since 1987 than breast cancer [7]. The sponge-like lungs are located in the chest. They are responsible for supplying the body with oxygen and expelling carbon dioxide. Air enters lungs through windpipe when an individual breathes in (trachea). The trachea separates into bronchi, which are tubes that enter the lungs. These separate into bronchioles, which are smaller branches. The tiny air sacs known as alveoli are located at the end of the bronchioles. Blood receives oxygen from the air thanks to the alveoli. The blood's carbon dioxide is removed by them which is expelled from the body as an individual exhales. The right lung has three parts (lobes). Two lobes make up the left lung [8-15].

Lung cancer was regarded as relatively uncommon at the beginning of the 20th century, but by the end of the century it was the main cause of cancer-related death in males in more than 25 developed nations. The most common cancer-related death worldwide in the twenty-first century was lung cancer which had eclipsed breast cancer by 2022 and now kills more women from cancer in affluent nations. Though increases in environmental air pollution were considered to have played a role, the rapid rise in the prevalence of lung cancer around the world was mostly attributed to the increased use of cigarettes after World War I [16-20]. Cough is the

most prevalent but non-specific sign of lung cancer. Lung cancer is far more likely to occur if there are any associated symptoms, such as hemoptysis or shortness of breath, or systemic symptoms such as anorexia or weight loss. Appropriate diagnosing generally consists of recommended imaging, refer to a multidisciplinary lung cancer team, and confirm the diagnosis with mediastinoscopy, thoracentesis, fine-needle aspiration, or sputum cytology. Depending on the stage, histology, immunotherapy biomarker testing, and patient health status, if lung cancer is found, there are various treatment choices. Surgery, immunotherapy, chemotherapy, and/or radiotherapy are all forms of treatment [21-24].

2. ETIOLOGY

Approximately, 90% of lung cancer cases are thought to be caused by smoking. Male smokers are at the greatest risk. Exposure to additional toxins, such as asbestos increases the risk. Due to the intricate interactions between smoking, environmental variables, and genetics, there is no connection between the number of packs smoked annually and lung cancer. Passive smoking increases the risk of lung cancer by 20 to 30% [25]. Radiation for the treatment of cancers other than lung cancer, particularly non-Hodgkins lymphoma and breast cancer is another factor [26,27]. Lung cancer is also linked to exposure to metals like chromium, nickel, arsenic, and polycyclic aromatic hydrocarbons. Independent of smoking, lung conditions like idiopathic pulmonary fibrosis raise the risk of lung cancer [28,29]. Additionally known risk factors for lung cancer include radon and asbestos. Lung cancer risk is increased by asbestos exposure, especially occupational exposure, in a dose-dependent way that varies depending on the type of asbestos fiber. Risk of asbestos exposure outside of the workplace is less clear. The Environmental Protection Agency (EPA) of the United States has set guidelines for low-level tolerable non-occupational asbestos exposure, asserting that the health risk to building occupants of asbestos that is left undisturbed and free of repairable particles is negligible [30-32]. Lung cancer risk among uranium miners who were exposed to radon was minimal but considerable. As a byproduct of uranium and radium decay, radon has also been demonstrated to build up in residences. Residential radon poses significant risks, especially for smokers, and is believed to be responsible for about 2% of lung cancer deaths




Fig. 1. Lung cancer statistics 2022 [7]




Fig. 2. Different causes of lung cancer

in Europe, according to a meta-analysis of data from that continent [33,34].

3. EPIDEMIOLOGY

Lung cancer is the second most prevalent cancer worldwide and the leading cause of cancer death. Lung cancer was responsible for 1.8 million new cases of death in 2020, or 18% of all cancer-related deaths[35]. Compared to other major malignancies, lung cancer had a substantially poorer 5-year survival rate (7%–25%)[36]. Due to lung cancer's high death rate which produced a significant worldwide burden of disease, the distribution of mortality was extremely comparable to that of its incidence [37,38]. Treatment developments in some high-income nations, such as the United States, the United Kingdom, Australia, and New Zealand have recently improved lung cancer mortality [39,40].

The majority of cancer diagnoses globally (12.4% of all cancer diagnoses worldwide) are lung cancer cases which also account for the majority of cancer-related deaths. According to the American Cancer Society, there are over 154,000 lung cancer-related fatalities and over 234,000 new instances of lung cancer in the country every year. With a projected 1.8 million deaths, lung cancer continued to be the most common type of cancer death worldwide, according to the Global Cancer Statistics report from 2020[41,42].

4. PATH PHYSIOLOGY OF LUNG CANCER

Lung cancer's pathophysiology is extremely complicated and still not fully understood. Regular exposure to toxins like cigarette smoke is believed to be a contributing cause of lung epithelial dysplasia. When exposure is sustained, genetic alterations and changes in protein synthesis result. In return, this disturbs the cell cycle and encourages the development of cancer. MYC, BCL2, and p53 for small cell lung cancer (SCLC) and EGFR, KRAS, and p16 for non-small cell lung cancer (NSCLC) are the genetic mutations most frequently linked to the development of lung cancer [43-45]. Lung cancers are classified histopathologically based on cellular and molecular subtypes which is a crucial step in the diagnosis and treatment of lung malignancies. Lung malignancies are divided into the following categories are shown in Table 1.

5. SYMPTOMS

Lung cancer typically first appears in patients between the ages of 5 and 6. At the time of presentation, about three-fourths of patients exhibit clinical symptoms, the most prevalent of which are cough (50-75%), hemoptysis (25-50%), dyspnea (25%), and chest discomfort (20%). Generalized symptoms consist of anorexia, weight loss, or weariness that are connected to the malignancy's systemic manifestations. The occurrence of regional or distant metastases, the presence of paraneoplastic syndromes, and the local consequences of the main tumor all affect the clinical symptoms. The symptoms of lung cancer may be brought on by the release of hormones or bioactive compounds, or they may be caused by immune-mediated destruction of neural tissue brought on by antibody or cell-mediated immune responses. The most prevalent of these paraneoplastic syndromes which affect 10–20% of lung cancer patients, are connected to the release of antidiuretic and adrenocorticotropin hormones. These hormones can cause serum hyposmolarity and hyponatremia as well as Cushing's syndrome (central obesity, hypertension, glucose intolerance, plethora, and hirsutism), respectively [46-51].

6. STAGES OF LUNG CANCER

The prognosis and treatment options for lung cancer are influenced by its stage. The stage describes the size of the tumor, its location inside the lung, whether it has moved to other parts of the body or not, and whether it has invaded other tissue (Table 2).

7. DIAGNOSIS

During tests for other diseases, lung tumors are frequently found. Sputum may contain cancer cells, a lung biopsy may be performed to remove a sample of lung tissue for examination, or a bronchoscope may be used to look directly for cancer in the big airways of the lungs (bronchi). X-rays, computerized axial tomography (CAT) scans, positron emission tomography (PET) scans, and magnetic resonance imaging are examples of noninvasive techniques (MRI). Additionally, a number of blood tests can be used to look for proteins and other elements linked to lung cancer. For instance, aberrant variations in parathormone serum levels, the presence of the protein cytokeratin 19 fragment in the blood, or compounds known as carcinogenic antigens may be signs of malignant lung disease. Blood tests

to identify DNA released by cells harboring genetic abnormalities linked to lung cancer are also being developed by researchers which raises the possibility of finding lung tumors before they turn malignant.[52,53].

8. CURRENT TREATMENT OPTIONS

Surgery, chemotherapy, and radiation are all used to treat lung cancer, as they are for the majority of cancers. The type of cancer, the stage or severity of the disease, and the patient's general condition all influence the treatment option. The results of genetic testing which can spot changes that make some lung tumors

receptive to particular medications, may also influence the sort of treatment a patient receives [76-80].

During surgery, a lung lobe, a portion of the lung, or the entire lung may be removed if it is malignant (pneumonectomy). Surgery on the lungs is risky and might result in side effects including bleeding or pneumonia. Even though the removal of the complete lung does not prevent generally healthy individuals from eventually returning to their normal activities, the pre-existing bad state of many patients' lungs causes long-term breathing difficulties after surgery [81-84].

Table 1. Categories of lung malignancies

Lung cancer type	Location in the lung	Features	References
Adenosquamous carcinoma	peripheral lung	<ul style="list-style-type: none"> • Uncommon • Highly aggressive lung tumor 	[54]
Adenocarcinoma	Peripheral lung	<ul style="list-style-type: none"> • Most prevalent type of lung cancer in non-smokers and more prevalent in women; • Develops from type II alveolar and small airway epithelial cells; • Should be tested for the EGFR mutation for potential targeted therapy; • Occasionally appears at the site of scarring; • Tends to form glands and secrete mucin; 	[55]
Squamous cell carcinoma	2/3 central 1/3 peripheral	<ul style="list-style-type: none"> • Clearly connected to cigarette smoking • Develops from proximal big airway epithelial cells • Have a tendency to produce blockage and distal atelectasis. • The greatest prognosis is due to intrathoracic spread rather than distant metastasis 	[56-59]
Small-Cell Lung Carcinoma (SCLC)	Central	<ul style="list-style-type: none"> • Most potent link to smoking • Is produced by the same pulmonary neuroendocrine cells that produce neurotransmitters, growth factors, and vasoactive chemicals. • Commonly secretes ADH (SIADH) or ACTH and causes paraneoplastic syndrome (ectopic Cushing syndrome) • The worst prognosis is caused by rapid growth and early distant metastases (brain, liver, bone). 	[55]
Large cell carcinoma	Peripheral	<ul style="list-style-type: none"> • Behaves similarly to adenocarcinomas but with slightly larger lesions 	[55]




Fig. 3. Common symptoms of lung cancer

Table 2. Stages of lung cancer

Stages	Description
Occult stage	Can find cancer cells in the mucus patient cough up. Neither a biopsy nor imaging scans can reveal tumor. Another name for it is 'concealed cancer'[60-62].
Stage 0	The tumor is quite little and deeper lung tissues or the outside of lungs are free of cancerous cells[63-65].
Stage I	Lymph nodes do not have cancer, only the tissues of lungs do[66-69].
Stage II	Lymph nodes close to lungs may have become infected[70-72].
Stage III	The lymph nodes and the center of chest have been further affected by its spread[73, 74].
Stage IV	The body is covered widely with cancer. The brain, bones, or liver may have been affected[75].

Radiation can be used on its own or in combination with surgery, either before the operation to reduce tumor size or after the operation to eradicate small pockets of malignant tissue. Radiation therapy can be delivered using external beams or through the surgical implantation of radioactive pellets (brachytherapy). Vomiting, diarrhea, exhaustion, or worse lungs damage are examples of side effects. Chemotherapy employs chemicals to kill malignant cells, but these chemicals also, to variable degrees, damage healthy cells, leading to side effects akin to those of radiation therapy. Microwave ablation, an experimental technique that uses heat produced by microwave energy to kill cancer cells, has showed promise in the treatment of lung cancer. Microwave ablation has been shown in preliminary research to decrease

and maybe even remove some lung tumors in small subsets of patients [85-90].

The evolution of medication resistance, which is unavoidable, is the major barrier to targeted cancer therapy. Different strategies are used by tumor cells to fend off the targeting agent. Secondary resistance mutations on the target kinase domain most frequently appear in EGFR-mutant non-small cell lung cancer and reduce the binding affinity of first- and second-generation drugs. The activation of parallel bypass pathways and phenotypic change are additional resistance defense mechanisms. Sequential monotherapies promise to temporarily address the issue of acquired drug resistance, but it is clear that their effectiveness is constrained by the tumor cells' capacity to adapt and develop novel resistance

mechanisms in order to survive in the drug environment [91-95].

The minimal residual disease cells, a small subpopulation of cells that can withstand the drug and eventually develop additional mutations that allow them to regrow and become the dominant population in the therapy-resistant tumor, have been nominated as a model of drug resistance and tumor progression under targeted therapy in recent studies. This subgroup of cells appears to have undergone a subclonal event, giving rise to driver mutations distinct from the one that causes tumors in the most common ancestor. In order to identify the resistance drivers that emerge from branching development, it is crucial to comprehend intratumoral heterogeneity which is what causes minimal residual illness.[96-100].

Over the past ten years, numerous technical, pharmaceutical, and service advancements have been made in the staging and treatment of lung cancer, but doubts about how to most effectively use these advancements and their cost-effectiveness persist. To determine whether newer radiation methods, such as SABR, are similar to surgery for lung cancer in its early stages, more research is required. The cost-effectiveness of the more recent targeted medicines is still a hot topic, as is the question of

whether investing more money on early supportive care would be wise. Even if there are novel therapies available, access to them is uneven, and more thought needs to be given to resource commissioning to address the 'hub and spoke effect.'

8.1 A New Strategy for Current Lung Cancer Treatment

For patients with NSCLC, targeted treatments and immunotherapies have become realistic therapy choices, while therapeutic advances for SCLC have not yet been made. Although the majority of SCLC patients initially benefit from frontline cytotoxic therapy, recurrence is all but guaranteed. There are typically few therapeutic choices available for patients because the ensuing disease is frequently severe and resistant to additional therapy [101-106].

SCLC exhibits increased expression of the DNA damage repair enzyme poly (ADP-ribose) polymerase (PARP), making it a possible therapeutic target for this particular tumor type. The inclusion of DNA-damaging drugs has been shown to synergize with PARP inhibitors, providing a promising method for the treatment of recurrent SCLC tumors, whereas the inhibition of PARP alone has demonstrated little to no benefit in this situation [107].




Fig. 4. Percentage distribution of lung cancer by stages [108]

The researchers carried out a co-clinical trial in patient-derived xenograft (PDX) models taken from 22 patients to clarify potential biomarkers that could predict responsiveness to this exploratory treatment regimen. They discovered that a molecular signature made up of four genes involved in the inflammatory response could differentiate between sensitive and resistant models, and that low basal expression of these genes was associated with resistance to both the treatment combination under study and platinum etoposide, the standard first-line chemotherapy for SCLC patients [107].

9. CONCLUSIONS

Lung cancer is one of the most frequent malignancies that results in death globally. Lung cancer, also known as lung carcinoma, is a malignant lung tumor that is characterized by unrestrained cell proliferation in the lung tissues. If untreated, this tumor has the potential to metastasize, or grow outside of the lung, into nearby tissue or other parts of the body. The majority of primary lung malignancies, sometimes referred to as cancers that start in the lung, are epithelial cell carcinomas. The two main types of lung cancer are non-small-cell lung carcinoma and small-cell lung carcinoma. More research is needed to evaluate whether more recent radiation techniques, including SABR, are comparable to surgery for treating lung cancer in its early stages. The question of whether spending more money on early supportive care would be prudent is still a heated topic, as is the cost-effectiveness of the more recent targeted medications. Even if novel medicines are available, there is uneven access to them, and resource commissioning needs to be given more consideration to overcome the hub and spoke effect.

CONSENT AND ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Sethi T, Lung cancer. Introduction. *Thorax*. 2002;57(11):992-3.
2. Agrawal A et al. Altered innate immune functioning of dendritic cells in elderly humans: A role of phosphoinositide 3-kinase-signaling pathway. *The Journal of Immunology*. 2007;178(11):6912-6922.
3. Albright JM. et al. Advanced age alters monocyte and macrophage responses. *Antioxidants & redox signaling*, 2016;25(15):805-815.
4. Alder JK, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. *Proceedings of the National Academy of Sciences*. 2008;105(35):13051-13056.
5. Available:<Non-Small Cell Lung Cancer Treatment (PDQ®)–Patient Version - NCI.pdf>
6. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-424.
7. Siegel RL, et al. Cancer statistics 2022. *CA: A Cancer Journal for Clinicians*. 2022;72(1):7-33.
8. Alpert A. et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. *Nature Medicine*. 2019;25(3):487-495.
9. Association AL. Trends in pneumonia and influenza morbidity and mortality. Chicago: American Lung Association; 2010.
10. Group ATBCCPS. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *New England Journal of Medicine*. 1994;330(15):1029-1035.
11. Amor C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. *Nature*. 2020;583(7814):127-132.
12. Anderson EJ. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. *New England Journal of Medicine*. 2020;383(25):2427-2438.
13. Angelidis I. et al. An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. *Nature Communications*. 2019;10(1):963.
14. Araya J, et al. Insufficient autophagy in idiopathic pulmonary fibrosis. *American Journal of Physiology-Lung Cellular and Molecular Physiology*. 2013;304(1):L56-L69.
15. Armanios MY et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. *New England Journal of Medicine*. 2007;356(13):1317-1326.

16. Sasaki S. et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. *The Journal of Clinical Investigation*. 2011;121(8):3109-3119.
17. Sayin VI. et al. Antioxidants accelerate lung cancer progression in mice. *Science Translational Medicine*. 2014;6(221):221ra15-221ra15.
18. Schafer MJ et al. Cellular senescence mediates fibrotic pulmonary disease. *Nature communications*. 2017;8(1):14532.
19. Schumacker PT. Lung cell hypoxia: role of mitochondrial reactive oxygen species signaling in triggering responses. *Proceedings of the American Thoracic Society*. 2011;8(6):477-484.
20. Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. *Clinical Interventions in Aging*. 2006;1(3):253-260.
21. Available:<Lung Cancer_ Diagnosis, Treatment Principles, and Screening _ AAFP.pdf>
22. Nijakowski K. et al. Salivary metabolomics for systemic cancer diagnosis: A systematic review. *Metabolites*. 2022; 13(1).
23. Utsumi N. et al. A retrospective study of patients undergoing palliative radiotherapy for airway obstruction due to lung cancer. *Cancer Diagn Progn*. 2023;3(1):61-66.
24. Hosseini K. et al. Role of fungal infections in carcinogenesis and cancer development: A literature review. *Adv Pharm Bull*. 2022;12(4):747-756.
25. Alberg AJ, Samet JM. Epidemiology of lung cancer. *Chest*. 2003;123(1 Suppl):21s-49s.
26. Raaschou-Nielsen O. et al. Particulate matter air pollution components and risk for lung cancer. *Environment International*. 2016;87:66-73.
27. Cohen AJ. et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. *The Lancet*. 2017;389(10082):1907-1918.
28. Ramo DE, Liu H, Prochaska JJ. Tobacco and marijuana use among adolescents and young adults: A systematic review of their co-use. *Clinical Psychology Review*. 2012; 32(2):105-121.
29. Boyer MJ et al. Improved survival of stage I non-small cell lung cancer: A VA central cancer registry analysis. *Journal of Thoracic Oncology*. 2017;12(12):1814-1823.
30. Lorigan P et al. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. *Lancet Oncol*. 2005;6(10):773-9.
31. Burns DM. Primary prevention, smoking and smoking cessation: implications for future trends in lung cancer prevention. *Cancer*. 2000;89(11 Suppl):2506-9.
32. Wagner GR. Asbestosis and silicosis. *Lancet*. 1997;349(9061):1311-5.
33. Grosche B. et al. Lung cancer risk among German male uranium miners: A cohort study, 1946-1998. *Br J Cancer*. 2006;95(9):1280-7.
34. Darby S et al. Radon in homes and risk of lung cancer: Collaborative analysis of individual data from 13 European case-control studies. *BMJ*. 2005;330(7485):223.
35. Sung H et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. 2021;71(3):209-249.
36. Weiss J. et al. Public attitudes about lung cancer: stigma, support, and predictors of support. *Journal of Multidisciplinary Healthcare*. 2014;293-300.
37. Jemal A et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. *JNCI: Journal of the National Cancer Institute*. 2008;100(23):1672-1694.
38. Howlader N. et al. The effect of advances in lung-cancer treatment on population mortality. *New England Journal of Medicine*. 2020;383(7):640-649.
39. Torre LA, Siegel RL, Jemal A. lung cancer statistics. *Lung Cancer and Personalized Medicine: Current Knowledge and Therapies*. 2016;1-19.
40. Luo Q et al. Lung cancer mortality in Australia: projected outcomes to 2040. *Lung Cancer*. 2018;125:68-76.
41. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin*. 2017; 67(1):7-30.
42. Sung H et al. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209-249.
43. Cagle PT, Allen TC, Olsen RJ. Lung cancer biomarkers: present status and

- future developments. *Arch Pathol Lab Med.* 2013;137(9):1191-8.
44. Lindeman NI et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *J Mol Diagn.* 2013;15(4):415-53.
 45. Lindeman NI et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the college of american pathologists, the international association for the study of lung cancer, and the association for molecular pathology. *J Mol Diagn.* 2018;20(2):129-159.
 46. Ost DE et al. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd Ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* 2013;143(5 Suppl): e121S-e141S.
 47. Chao F, Zhang H. PET/CT in the staging of the non-small-cell lung cancer. *J Biomed Biotechnol.* 2012;783739.
 48. Steinert HC. PET and PET-CT of lung cancer. *Methods Mol Biol.* 2011;727:33-51.
 49. Prenzel KL et al. Lymph node size and metastatic infiltration in non-small cell lung cancer. *Chest.* 2003;123(2):463-7.
 50. Hasegawa M et al. Growth rate of small lung cancers detected on mass CT screening. *Br J Radiol.* 2000;73(876):1252-9.
 51. Kakinuma R et al. Progression of focal pure ground-glass opacity detected by low-dose helical computed tomography screening for lung cancer. *J Comput Assist Tomogr.* 2004;28(1):17-23.
 52. Kim J, Lee H, Huang BW. Lung cancer: Diagnosis, treatment principles, and screening. *Am Fam Physician.* 2022;105(5):487-494.
 53. Latimer KM. Lung cancer: Clinical Presentation and Diagnosis. *FP Essent.* 2018;464:23-26.
 54. Filosso PL et al. Adenosquamous lung carcinomas: A histologic subtype with poor prognosis. *Lung Cancer.* 2011;74(1):25-9.
 55. Kadota K et al. The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: A conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. *Mod Pathol.* 2014;27(5):690-700.
 56. Rajdev K et al. An unusually aggressive large cell carcinoma of the lung: Undiagnosed until autopsy. *Cureus.* 2018; 10(2):e2202.
 57. Aisner SC et al. The clinical significance of variant-morphology small-cell carcinoma of the lung. *J Clin Oncol.* 1990;8(3):402-8.
 58. Sahn SA. Malignancy metastatic to the pleura. *Clin Chest Med.* 1998;19(2):351-61.
 59. Chute CG et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. *Cancer.* 1985; 56(8):2107-11.
 60. Elia S et al. Does aggressive management of solitary pulmonary nodules pay off? *Breathe (Sheff).* 2019;15(1):15-23.
 61. Soneji S et al. Occurrence of discussion about lung cancer screening between patients and healthcare providers in the USA, 2017. *J Cancer Educ.* 2020;35(4):678-681.
 62. Visentin A et al. Palliative therapy in adults with cancer: A cross-sectional study. *Rev Bras Enferm.* 2018;71(2):252-258.
 63. Tammemägi MC et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. *Plos Med.* 2014;11(12):e1001764
 64. Sculier JP et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM classification of malignant tumors and the proposals for the 7th Edition. *J Thorac Oncol.* 2008;3(5):457-66.
 65. D'Angelo SP et al. Distinct clinical course of EGFR-mutant resected lung cancers: Results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. *J Thorac Oncol.* 2012;7(12):1815-1822.
 66. Hoang T et al. Clinical model to predict survival in chemo-naïve patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. *J Clin Oncol.* 2005;23(1):175-83.
 67. Bugalho A et al. Trans-esophageal endobronchial ultrasound-guided needle

- aspiration (EUS-B-NA): A road map for the chest physician. *Pulmonology*; 2017.
68. Lizama C et al. Implementing endobronchial ultrasound-guided (EBUS) for staging and diagnosis of lung cancer: A cost analysis. *Med Sci Monit*. 2018;24:582-589.
 69. Créquit P et al. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: A systematic review and network meta-analysis. *BMC Med*. 2017;15(1):193.
 70. Ramos-Esquivel A et al. Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: A systematic review and meta-analysis of randomised clinical trials. *ESMO Open*. 2017;2(3):e000236.
 71. Mulvenna P et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): Results from a phase 3, non-inferiority, randomised trial. *Lancet*. 2016;388(10055):2004-2014.
 72. Heineman DJ et al. The dutch national clinical audit for lung cancer: A tool to improve clinical practice? An analysis of unforeseen ipsilateral mediastinal lymph node involvement in the Dutch Lung Surgery Audit (DLISA). *Eur J Surg Oncol*. 2018;44(6):830-834.
 73. Labarca G et al. [Endobronchial ultrasound-guided transbronchial needle aspiration]. *Rev Med Chil*, 2017;145(9): 1165-1171.
 74. Fréchet B et al. Diagnostic accuracy of mediastinal lymph node staging techniques in the preoperative assessment of nonsmall cell lung cancer patients. *J Bronchology Interv Pulmonol*. 2018;25(1): 17-24.
 75. Ilias I et al. Cushing's syndrome due to ectopic corticotropin secretion: Twenty years' experience at the National Institutes of Health. *J Clin Endocrinol Metab*. 2005;90(8):4955-62.
 76. Lemjabbar-Alaoui H et al. Lung cancer: Biology and treatment options. *Biochim Biophys Acta*. 2015;1856(2):189-210.
 77. Berrington de González A, Kim KP, Berg CD. Low-dose lung computed tomography screening before age 55: Estimates of the mortality reduction required to outweigh the radiation-induced cancer risk. *J Med Screen*. 2008;15(3):153-8.
 78. Gray A et al. Lung cancer deaths from indoor radon and the cost effectiveness and potential of policies to reduce them. *BMJ*. 2009;338:a3110.
 79. Friedman DL et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. *J Natl Cancer Inst*. 2010;102(14):1083-95.
 80. Straif K et al. A review of human carcinogens--Part C: Metals, arsenic, dusts, and fibres. *Lancet Oncol*. 2009; 10(5):453-4.
 81. Katanoda K et al. An association between long-term exposure to ambient air pollution and mortality from lung cancer and respiratory diseases in Japan. *J Epidemiol*. 2011;21(2):132-43.
 82. Cao J et al. Association between long-term exposure to outdoor air pollution and mortality in China: A cohort study. *J Hazard Mater*. 2011;186(2-3):1594-600.
 83. Hales S, Blakely T, Woodward A. Air pollution and mortality in New Zealand: Cohort study. *J Epidemiol Community Health*. 2012;66(5):468-73.
 84. Masclee GM et al. Risk of upper gastrointestinal bleeding from different drug combinations. *Gastroenterology*. 2014;147(4):784-792. e9.
 85. Howington JA et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 Suppl):e278S-e313S.
 86. Timmerman R et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. *Jama*. 2010;303(11):1070-6.
 87. Burdett S, Stewart L. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. *Lung Cancer*. 2005;47(1):81-3.
 88. Chansky K et al. The IASLC lung cancer staging project: External validation of the revision of the tmn stage groupings in the eighth edition of the TNM classification of lung cancer. *J Thorac Oncol*. 2017;12(7): 1109-1121.
 89. van den Berg LL et al. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. *J Thorac Oncol*. 2015;10(5): 826-831.

90. Pignon JP et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative Group. *J Clin Oncol.* 2008; 26(21):3552-9.
91. Dearden S et al. EGFR T790M mutation testing within the osimertinib AURA Phase I study. *Lung Cancer.* 2017;109:9-13.
92. Karlovich C et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). *Clin Cancer Res.* 2016;22(10):2386-95.
93. Wu YL et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: Analyses from the phase III, randomized, open-label, ENSURE study. *Ann Oncol.* 2015;26(9):1883-1889.
94. Marchetti A et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. *J Thorac Oncol.* 2015;10(10):1437-43.
95. Jenkins S et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer. *J Thorac Oncol.* 2017;12(7):1061-1070.
96. Kibirova A et al. The journey of an EGFR-mutant Lung adenocarcinoma through erlotinib, osimertinib and ABCP immunotherapy regimens: Sensitivity and resistance. *Case Rep Oncol.* 2019;12(3): 765-776.
97. Bozic I et al. Evolutionary dynamics of cancer in response to targeted combination therapy. *Elife.* 2013;2:e00747.
98. Zhang LL et al. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer. *Int J Cancer.* 2017;140(1):103-108.
99. Diaz LA Jr., Bardelli A. Liquid biopsies: Genotyping circulating tumor DNA. *J Clin Oncol.* 2014;32(6):579-86.
100. Buder A, Tomuta C, Filipits M. The potential of liquid biopsies. *Curr Opin Oncol.* 2016;28(2):130-4.
101. George J et al. Comprehensive genomic profiles of small cell lung cancer. *Nature.* 2015;524(7563):47-53.
102. Rudin CM et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. *Nature Genetics.* 2012;44(10):1111-1116.
103. Peifer M et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nature genetics.* 2012;44(10):1104-1110.
104. Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. *Translational Lung Cancer Research.* 2018;7(1):69.
105. Owonikoko TK et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. *Journal of Thoracic Oncology.* 2012;7(5):866-872.
106. Ardizzoni A et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office and the Lung Cancer Cooperative Group. *Journal of Clinical Oncology.* 1997;15(5):2090-2096.
107. Farago AF et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer: olaparib and temozolomide in SCLC. *Cancer Discovery.* 2019;9(10): 1372-1387.
108. Available: <Lung Cancer Canada - Lung Cancer Canada.pdf>

© 2023 Noor et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/96387>